Hypersensitivity may occur; discontinue immediately in case of anaphylactic reaction. Caution in patients w/ hypersensitivity to other azole antifungal agents. Reports of severe cutaneous adverse reactions eg, SJS; discontinue therapy if patient develops severe cutaneous adverse reaction. Risk of QT shortening; caution to patients taking other medicinal products known to decrease QT interval eg, rufinamide. Caution w/ concomitant CYP3A4/5 inhibitors eg, lopinavir/ritonavir (except for ketoconazole to which co-administration is contraindicated); CYP2B6 substrates, especially medicinal products w/ narrow therapeutic index eg, cyclophosphamide. Avoid concomitant use w/ mild CYP3A4/5 inducers eg, aprepitant, prednisone, pioglitazone. Appropriate therapeutic drug monitoring & dose adjustment may be necessary in concomitant use w/ CYP3A4 substrates eg, tacrolimus, sirolimus or ciclosporin. Dose adjustment of P-gp substrates may be needed, especially w/ narrow therapeutic index eg, digoxin, colchicine & dabigatran etexilate. Limited clinical data in the treatment of mucormycosis. Moderate potential to influence ability to drive & use machines. Monitor hepatic enzymes; elevated liver transaminases have been reported. Not recommended in patients w/ severe hepatic impairment (Child-Pugh Class C) unless potential benefit outweighs risks. Must not be used during pregnancy except in patients w/ severe or potentially life-threatening fungal infections, in whom isavuconazole may be used if the anticipated benefits outweigh possible risks to the fetus. Not recommended for women of childbearing potential who are not using contraception. Discontinue breast-feeding during therapy. Safety & efficacy in childn <18 yr have not been established. Limited clinical experience in elderly. Powd for infusion: Infusion-related reactions including hypotension, dyspnea, dizziness, paresthesia, nausea & headache were reported; stop infusion if these reactions occur.
Sign Out
